[摘 要] 目的：探讨构建靶向CD7抗原的嵌合共刺激受体（CCR）并制备该受体修饰的健康供者来源γδ T细胞，以评估其对急性T淋巴细胞白血病（T-ALL）的体内与体外杀伤作用。方法：构建携带CD7-DAP10-CCR的慢病毒载体，并转导健康人外周血γδ T细胞，制备靶向CD7抗原的CCR γδ T细胞（CD7-DAP10-CCR-γδ T），所获细胞借助表达CD64、CD86和CD137L的人工抗原提呈细胞（aAPC）进行体外扩增。采用Annexin Ⅴ/7-AAD方法检测CD7-DAP10-CCR-γδ T对T-ALL细胞（Jurkat）、CD7缺陷型Jurkat细胞（CD7⁻ Jurkat）及异体健康人原代αβ T细胞的体外杀伤作用，共设置了3组效靶比（E∶T = 1∶1、1∶3和1∶10），孵育时间为18~24 h。其中，Jurkat细胞作为CD7阳性靶细胞，CD7⁻ Jurkat作为CD7阴性靶细胞以验证杀伤特异性，而异体健康人原代αβ T细胞则作为CD7阳性正常细胞对照，用于评估CD7-DAP10-CCR-γδ T细胞的脱靶效应。此外，在T-ALL荷瘤免疫缺陷小鼠体内验证药效，通过定期对荷瘤免疫缺陷小鼠进行活体成像、体质量检测及生存期观察，评估CD7-DAP10-CCR-γδ T细胞在荷瘤免疫缺陷小鼠体内的药效。结果：成功利用aAPC体外制备出CD7-DAP10-CCR-γδ T细胞，其平均扩增倍数超过10 000倍。体外杀伤实验表明，该细胞对T-ALL细胞具有较高的杀伤能力（P < 0.01），对Jurkat 细胞具有较高的毒性（P < 0.01），对CD7⁻ Jurkat细胞杀伤作用有限，而对高表达CD7的正常原代αβ T细胞基本无杀伤作用；荷瘤免疫缺陷小鼠体内药效试验结果显示，相对于对照PBS组，经CD7-DAP10-CCR-γδ T细胞治疗后，荷瘤免疫缺陷小鼠的生存期显著延长（P < 0.01）。结论：体外借助aAPC能成功制备CD7-DAP10-CCR-γδ T细胞，并且CD7-DAP10-CCR-γδ T细胞在体外、小鼠体内均对T-ALL细胞具有较强的杀伤作用，表明CD7-DAP10-CCR-γδ T细胞具备对T-ALL的治疗潜力。

[摘 要] 目的：探讨miR-4465靶向高迁移率族蛋白A1（HMGA1）对肝细胞癌Hep3B细胞增殖、迁移和侵袭能力的影响。方法：收集2020年5月至2021年9月在皖南医学院第一附属医院确诊为肝细胞癌患者的16对癌组织和癌旁组织样本，采用qPCR分析miR-4465在肝细胞癌组织和Hep3B、Huh7细胞中的表达情况，双荧光素酶报告基因实验验证miR-4465与HMGA1的调控关系。按转染物的不同将Hep3B细胞分为mimics-NC组、miR-4465-mimics组、inhibitor-NC组、miR-4465 inhibitor组、si-NC组、si-HMGA1组；另外分组转染mimics-NC+pcDNA-NC、miR-4465 mimics+pcDNA-NC和miR-4465 mimics+pcDNA-HMGA1进行回复实验。采用qPCR和WB法检测各组细胞中HMGA1 mRNA和蛋白水平的变化，CCK-8法检测各组细胞增殖能力的变化，划痕实验检测各组细胞迁移能力的变化，Transwell实验检测各组细胞侵袭能力的变化。结果：miR-4465在肝细胞癌组织和细胞中的表达水平显著低于癌旁组织和正常肝细胞（P<0.05或P<0.001）。转染48 h后，过表达miR-4465的Hep3B细胞增殖、迁移和侵袭能力均显著下降（P<0.05、P<0.01或P<0.001）；敲低miR-4465后细胞的增殖、迁移和侵袭能力均明显升高（P<0.05、P<0.01或P<0.001）。双荧光素酶报告实验验证了HMGA1-3'UTR与miR-4465的靶向结合关系，miR-4465可以靶向下调HMGA1 mRNA和蛋白质的表达（均P<0.01）。过表达HMGA1能部分逆转过表达miR-4465对细胞增殖、迁移、侵袭的抑制作用及HMGA1表达的抑制作用（均P<0.05）。结论：miR-4465通过靶向下调HMGA1在肝细胞癌Hep3B细胞中的表达，从而抑制Hep3B细胞的恶性生物学行为。

[Abstract] Objective: To study the effect of micheliolide (MCL) on the sensitivity of colorectal cancer cells to oxaliplatin (OxP) and its possible mechanism. Methods: HCT116 and LoVo cells were treated with 2 μmol/L MCL and 100 μmol/L OxP alone or in combination. The cell viability and colony forming ability in vitro were detected by CCK-8 and plate cloning formation assay, respectively. After being transfected with GFP-LC3 lentivirus, HCT116 cells were respectively treated with 2 μmol/L and 5 μmol/L MCL for 24 h. The aggregation of autophagy bodies in HCT116 cells induced by MCL was observed under fluorescence microscope. The effects of MCL on the expressions of LC3B-Ⅰ, LC3B-Ⅱ, p62 and STAT3 were detected by WB assay; the molecular docking model of MCL and STAT3 was constructed by Autodock version. Results: After the treatment of 2 μmol/L MCL combined with 100 μmol/L OxP, the activity of HCT116 and LoVo cells as well as the colony forming ability of HCT116 cells significantly decreased (all P < 0.01). After HCT116 cells were treated with 2 and 5 μmol/L MCL, the autophagy rate of cells in the treatment groups was significantly higher than that of the control group (all P < 0.01), the LC3B Ⅱ/Ⅰ ratio was 3.25 and 5.78 times that of the control group, the expression level of p62 was 25.5% and 9.8% of the control group, and the phosphorylation level of STAT3 was 2.18 and 3.87 times that of the control group. Molecular docking results showed that MCL might directly bind to STAT3 protein in vivo. Conclusion: MCL may enhance the sensitivity of colorectal cancer cells to OxP by promoting autophagy through STAT3 pathway.